Caribou Biosciences, Inc. (NASDAQ:CRBU) Holdings Raised by PFM Health Sciences LP

PFM Health Sciences LP lifted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 5.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,306,671 shares of the company’s stock after purchasing an additional 223,299 shares during the quarter. PFM Health Sciences LP’s holdings in Caribou Biosciences were worth $8,441,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in Caribou Biosciences by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after acquiring an additional 6,768 shares during the period. AQR Capital Management LLC acquired a new position in Caribou Biosciences during the second quarter worth about $30,000. Intech Investment Management LLC acquired a new position in Caribou Biosciences during the third quarter worth about $43,000. Bayesian Capital Management LP acquired a new position in Caribou Biosciences during the first quarter worth about $151,000. Finally, Walleye Trading LLC acquired a new position in Caribou Biosciences during the first quarter worth about $155,000. 77.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CRBU has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Royal Bank of Canada restated an “outperform” rating and set a $14.00 price objective on shares of Caribou Biosciences in a report on Wednesday, August 7th. Finally, Citigroup cut their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $10.20.

Caribou Biosciences Price Performance

Shares of CRBU opened at $2.19 on Friday. The company has a market capitalization of $198.30 million, a price-to-earnings ratio of -1.33 and a beta of 2.26. Caribou Biosciences, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $8.33. The business’s 50-day moving average is $2.05 and its 200-day moving average is $2.14.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.